PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Novacyt (ALTERNEXT:ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces its audited financial statement for the year ending 31st December, 2014, approved by the Board of Directors on the 28th April 2015.
2014 was an outstanding year for Novacyt, with the acquisition of diagnostics specialist Lab21 in June 2014, significant sales growth across the combined Group and a successful capital raise of €3.1m completed in December 2014. The Company’s commercial transformation is continuing with strong sales growth reported for the first quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
2014 was an outstanding year for Novacyt, with the acquisition of diagnostics specialist Lab21 in June 2014, significant sales growth across the combined Group and a successful capital raise of €3.1m completed in December 2014. The Company’s commercial transformation is continuing with strong sales growth reported for the first quarter of 2015.
Help employers find you! Check out all the jobs and post your resume.
